83 results about "Intestinal Microbiome" patented technology

The invention belongs to the technical field of biology, and particularly relates to animal bifidobacterium subsp. Lactis FMBL B24304AHDM and application thereof.The animal bifidobacterium subsp. Lactis FMBL B24304AHDM is preserved in the China Center for Type Culture Collection on November 18, 2024, the preservation number is CCTCC NO: M 20242505, and the animal bifidobacterium subsp. Lactis FMBL B24304AHDM has the good inhibition capacity on pathogenic bacteria and has the high scavenging capacity on DPPH and ABTS free radicals; the compound has the effect of inhibiting the activity of alpha-glucosidase, alpha-amylase and dipeptidyl peptidase IV, and the oral glucose tolerance and insulin tolerance of T2DM mice can be remarkably reduced; the composition of intestinal microbiome is obviously improved, the abundance and variety of effective microbial communities in the intestinal tract are improved, and the relative abundance of pathogenic bacteria is reduced, so that the disorder of short-chain fatty acids of T2DM mice is improved, and the application prospect is wide.

The invention discloses application of lactobacillus rhamnosus to preparation of a product for improving and treating cognitive impairment. The invention discloses the new application of the rhamnosus cheese for the first time, and the rhamnosus cheese can improve or treat cognitive impairment related to aging by improving behavioral function change, brain inflammatory factors, oxidative stress activity and neurotransmitter level caused by aging of mice and regulating transcriptome, intestinal microbiome, metabolome and the like. The lactobacillus rhamnosus has a potential application prospect in the aspect of improving learning and memory ability impairment caused by senescence.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

The invention relates to the technical field of Bian chicken source lactobacillus sharianus, in particular to Bian chicken source lactobacillus sharianus YYBJ-07-01 as well as a preparation method and application of the Bian chicken source lactobacillus sharianus YYBJ-07-01. The Bian chicken source lactobacillus shariensis YYBJ-07-01 is preserved in the China Center for Type Culture Collection on September 23, 2025, the classification name of the Bian chicken source lactobacillus shariensis YYBJ-07-01 is that the Bian chicken source lactobacillus shariensis YYBJ-07-01 is classified and named, and the preservation number of the Bian chicken source lactobacillus shariensis YYBJ-07-01 is CCTCC (China Center for Type Culture Collection) No.M20252093. As a national protection variety, the strong environmental adaptability of Bian chickens is associated with a unique intestinal microbiome. According to the invention, not only is the precious genetic resource of Bian chicken deeply excavated and scientifically utilized, but also a solid material foundation is laid for developing a Bian chicken source lactobacillus sharianus YYBJ-07-01 product, and the application value of a local characteristic variety is improved.

Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.

The invention provides a risk prediction method and device based on digestive system department diseases, and the method comprises the steps: obtaining clinical data and intestinal microbiome data of a target object, and carrying out the preprocessing and standardization of a clinical data set and the intestinal microbiome data; inputting the preprocessed clinical data into a first encoder to obtain a clinical feature matrix; inputting the preprocessed intestinal microbiome into a second encoder to obtain an intestinal microbiome characteristic matrix; based on a cross-modal attention mechanism, performing bidirectional attention calculation on the clinical feature matrix and the intestinal microbiome feature matrix to obtain fusion features; the method comprises the following steps: performing two-way interaction and fusion on clinical data and microbiome data of a target object, calculating an SHAP value of a fusion feature, taking the fusion feature as an input of a preset risk prediction module, and obtaining a risk prediction value of a disease of the digestive system department, and obtaining the risk prediction value of the disease of the digestive system department through two-way interaction and fusion of the clinical data and the microbiome data of the target object. The method can assist doctors in interpreting which key clinical indexes or intestinal microorganism characteristics have relatively large multi-risk prediction influence, assist clinical decision, and further improve the interpretability of digestive system department disease risk prediction.

The present invention is directed to an oncolytic vector together with one or more antibiotics, one or more a probiotics or other microbiome-targeting compositions, and / or one or more fecal transplant for use in the treatment of cancer. The invention is also directed to a pharmaceutical composition comprising an oncolytic vector with one or more of the following: an antibiotic, a probiotic, a microbiome-targeting composition and a fecal transplant. The invention is also directed to a kit which comprises a first container, a second container, and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing an oncolytic vector, the second container containing one of the following: an antibiotic, a probiotic, a microbiome-targeting composition or a fecal transplant, and the package insert comprises instructions for treating a subject having cancer using the compositions of the first and second containers, wherein said probiotic, microbiome-targeting composition or fecal transplant comprises or promotes a bacterial species which improves the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject, and wherein said antibiotic is effective against a bacterial species which decreases the effect of the treatment with an oncolytic vector in a subject when said bacterial species is present in the gut microbiome of said subject.

The present drinking therapy is intended to build, promote and maintain the intestinal microbiome (flora balance) and consists of a beverage having at least the following components: a herbal probiotic enzyme beverage (probiotic); necessary prebiotics of vitamins, mineral substances and trace elements are combined; the invention relates to natural nutritional oil rich in omega-3 fatty acid and tocopherol. These ingredients are processed into emulsions, whereby the resulting beverage can be drunk periodically, preferably daily, as part of drinking therapy.

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising a bacterial consortium that promotes interferon (IFN) response in the gut microbiome of a subject and enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.

The present invention provides: a composition for diagnosing neurodegenerative diseases comprising an agent capable of detecting a urocanate reductase (UrdA) enzyme, a strain having the enzyme, or a metabolite thereof; and a method for providing information for diagnosing neurodegenerative diseases using the urocanate reductase (UrdA) enzyme, a strain having the enzyme, or a metabolite thereof.

Predicting a weight loss potential from gut microbiome data is described herein. In an example, a system accesses gut microbiome metagenomic sequence data for a subject and determines a measurement of one or more weight loss features from the gut microbiome metagenomic sequence data. The one or more weight loss features define a gut microbiome signature for weight loss response for the subject independent of a body mass index of the subject. The system determines a weight loss potential for the subject based on a comparison of the measurement of the subject to a plurality of reference measurements of the one or more weight loss features for a reference population showing variable weight loss responses. The system outputs the weight loss potential for the subject.

The invention discloses oral multi-drug delivery hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the delivery hydrogel, spirulina platensis and traditional Chinese medicine ingredient astragalus polysaccharide are used as raw materials and are added into network-shaped hydrogel formed by combining carboxymethyl chitosan / sodium alginate. The method is easy to implement, safe in component and high in encapsulation efficiency. The composite hydrogel is stated to have the following effects: after oral administration, the medicine can be protected to completely pass through the stomach, the intestinal retention is prolonged, and the medicine can be continuously released at the focus part; the immune checkpoint inhibitor related intestinal inflammation is relieved, and the anti-tumor effect of the immune checkpoint inhibitor is assisted; and noninvasive monitoring of the medicine in the body is realized. According to the invention, a bioactive material is used as a potential treatment strategy for enhancing anti-tumor reaction and relieving immune checkpoint inhibitor-related adverse reaction, and can be more widely applied to treatment of pathological changes related to intestinal microbiome imbalance.

Provided are a method for predicting a treatment response to cancer immunotherapy, the method comprising a step of evaluating, from feces isolated from a patient, the enrichment of a strain of the order TANB77 according to GTDB phylogenetic classification or taxa belonging to the order TANB77, and a step of predicting a treatment response of the patient to cancer immunotherapy on the basis of the enrichment of the order TANB77 or the taxa; a probiotics composition for improving a treatment response; a fecal microbiota transplantation composition; and a method for screening for candidate prebiotics by using same.

The invention belongs to the technical field of biology, and discloses a biomarker for diagnosing unexplained infertility and application of the biomarker. The invention discloses application of a substance for detecting a biomarker in preparation of a product for diagnosing infertility. According to the invention, intestinal microbiome sequencing, multi-dimensional metabonomics (serum / tissue targeting-non-targeting analysis) and high-precision immune cell factor maps are integrated for the first time; the level of amino acid intestinal flora secondary metabolites (such as cinnamic acid, benzoic acid, aspartic acid, lysine, arginine, glutamine, histidine and the like) in plasma of an unexplained infertility patient is remarkably reduced, and part of the metabolites (such as cinnamic acid) have anti-inflammatory immune regulation activity. The plasma amino acid intestinal flora secondary metabolite can be used as a noninvasive biomarker for diagnosing infertility caused by unknown reasons.

The invention discloses an application of a flammulina velutipes extract in preparation of related products for relieving and / or treating drug-induced liver injury. By constructing a drug-induced liver injury model, it is found that by means of the needle mushroom extract rich in needle mushroom polysaccharide in low dosage, liver pathological injuries such as cisplatin-induced hepatocyte swelling and necrosis can be remarkably relieved, the levels of serum liver function indexes of alanine transaminase and aspartate transaminase are reduced, and the liver injury resistance is improved. And meanwhile, the activity of superoxide dismutase and glutathione peroxidase in liver tissues is improved, the concentration of malonaldehyde is reduced, and excellent antioxidant characteristics are shown. In addition, the invention also discovers that the flammulina velutipes extract can improve the composition of intestinal microorganisms, promote colonization of beneficial bacteria, reduce the abundance of harmful bacteria and regulate the key metabolic pathway of the liver at the same time, and can provide a treatment strategy for the treatment of drug-induced liver injury.

Powder compositions comprising one or more therapeutic ingredients including fiber and processes of manufacturing the same. Such compositions can be used as a prebiotic dietary supplement to maintain and / or improve the gut microbiome and overall gut health of a human.

This document relates to methods and materials involved in assessing and / or treating a mammal having cancer (e.g., lymphoma). For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer (e.g., lymphoma) is likely to respond to or has a cancer or a gut microbiome that makes that mammal more responsive to a particular cancer treatment are provided. Methods and materials for treating a mammal having cancer (e.g., lymphoma) are also provided.

The invention discloses a premature infant retinopathy risk prediction method and system based on a Bayesian network. The method comprises the following steps: S1, data acquisition and grouping; s2, performing quality control and standardization processing on clinical variables, and preprocessing microbiome data; s3, based on a structure learning algorithm, constructing a directed acyclic graph Bayesian network model which jointly reflects a dependency relationship between clinical variables and microbiome variables, optimizing the structure in combination with clinical prior medical knowledge, generating a conditional probability table of each variable, and realizing multi-factor joint risk reasoning and interpretation; s4, model training and performance evaluation; and S5, inputting data, analyzing, outputting the risk probability of occurrence of ROP of the child patient, and visually displaying the risk probability. By integrating multi-dimensional clinical variables and intestinal microbiome characteristics, a Bayesian network model which is reasonable in structure, high in interpretability and high in prediction accuracy is constructed, and early layered prediction and individualized intervention suggestions on the retinopathy risk of the premature infant are achieved.

The application discloses a system for generating a personalized nutritional prescription for sarcopenia and a computer readable storage medium, and relates to the technical field of medical nutritional intervention and health management. The system comprises basic information input, special examination result input, daily nutritional intake output and a nutritional prescription generation module. Based on the patient's basic information, clinical information, gene test report and intestinal microbiome data, the system generates a clinical nutritional benchmark framework, gene-related, flora-related and disease-related nutritional constraint items, and forms a unified constraint set in combination with individual preferences and execution feasibility. The nutritional prescription generation module constructs a food nutritional component matrix and a target function according to the unified constraint set, a list of selected foods and a nutritional supplement specification, solves an optimal food consumption vector under the conditions of meeting hard constraints and soft constraints, generates a daily food intake list, a per-meal food list and a nutritional supplement scheme, and improves the individualization, medical consistency and clinical executability of the nutritional prescription.

The present invention relates to: an intestinal microbiome biomarker composition for distinguishing equol producers; and use thereof. Intestinal microbiome biomarkers are differently expressed between equol producers and non-producers, and thus equol producers can be distinguished by confirming the expression of the biomarkers. Therefore, it is expected that the intestinal microbiome biomarkers for distinguishing equol producers, of the present invention, can be used to simply distinguish between equol producers and non-producers.

Engineered Bacteroides thetaiotaomicron (Bt) strains, including deletion mutant strains, and methods of use thereof are provided. Methods of delivering a therapeutic compound to a gut microbiome of a subject include generating an engineered Bacteroides thetaiotaomicron (Bt) strain to overproduce outer membrane vesicles (OMVs); loading a target therapeutic compound into the OMVs; and colonizing the gut microbiome of the subject with the engineered Bt strain. In some embodiments, the subject has at least one of lactose intolerance, phenylketonuria, inflammatory bowel disease, and a chronic intestinal condition.

The present invention relates to edible plant parts or tissues comprising probiotic bacteria and use thereof for oral delivery of the probiotic bacteria to an organism and enriching and / or improving the organism gastrointestinal tract microbiome. The present invention further relates to methods for selecting and / or producing probiotic bacteria capable of colonizing a plant tissue.

The invention provides a liver cancer early warning and risk assessment method based on intestinal microbiome, and relates to the technical field of medical auxiliary analysis, by collecting excrement and plasma samples of high-risk groups and combining 13C-cholic acid dynamics, functional gene abundance and intestinal barrier indexes, a multi-modal risk score is calculated, and dynamic monitoring is realized through longitudinal CUSUM. When the risk index exceeds a threshold value, the system can give out an early warning to assist iconography review and personalized intervention. According to the method, high-risk individuals of liver cancer can be identified in serum AFP and iconography unabnormal stages, early intervention and follow-up visit optimization are achieved, prediction sensitivity is high, interpretability is high, and the method is suitable for high-risk groups of HBV / liver cirrhosis and metabolic liver diseases and has remarkable clinical application value and generalizability.

Liquid compositions comprising one or more therapeutic ingredients including fiber and processes of manufacturing the same. Such compositions can be used as a prebiotic dietary supplement to maintain and / or improve the gut microbiome and overall gut health of a human.

Powder compositions comprising one or more therapeutic ingredients including fiber and processes of manufacturing the same. Such compositions can be used as a prebiotic dietary supplement to maintain and / or improve the gut microbiome and overall gut health of a human.

This invention belongs to the field of intestinal microbiome technology, and particularly relates to the application of a capsular polysaccharide derived from Bacteroides Salilsii CSP6 in the treatment and / or prevention of inflammatory bowel disease. The Bacteroides Salilsii strain is... Bacteroides salyersiae CSP6. This strain was isolated from the intestine of healthy humans and deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20221993. In vivo experiments showed that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can protect the colorectal mucosa from damage and promote the repair of damaged intestinal mucosa, thereby improving symptoms such as loose stools, rectal bleeding, and shortened colon and rectum, reducing weight loss caused by intestinal damage and inflammation, and ultimately exerting a therapeutic effect on inflammatory bowel disease.

The disclosure provides a computer-implemented method and system for detecting microbiome age of a subject. The method comprises obtaining a microbiota species profile from a fecal sample of the subject; predicting a gut microbiome and thus, gut health status as a value on a scale from diseased microbiome to healthy microbiome using a first machine learning model; in case the gut microbiome health status value is above a threshold, further predicting a microbiome age of the subject's gut microbiome using a second machine learning model; and providing a personalized report based on the gut microbiome health status value and, in case the gut microbiome health status value is above the threshold, a comparison between the microbiome age and the subject's chronological age.

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.